NCT04103333View on ClinicalTrials.gov

Angelman Syndrome (AS) Biomarker Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

January 2, 2022

Study Completion Date

January 2, 2022

Conditions
Angelman SyndromeChromosome 15q Duplication (dup15q) Syndrome
Interventions
PROCEDURE

Lumbar Puncture

Administered as specified in the treatment arm.

PROCEDURE

Blood Collection

Administered as specified in the treatment arm.

Trial Locations (5)

27514

University of North Carolina Hospital, Carolina

37235

Vanderbilt University Medical Center, Nashville

60612

Rush Medical College, Chicago

92123

Rady Childrens Hospital, San Diego

02115

Boston Children's Hospital, Boston

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT04103333 - Angelman Syndrome (AS) Biomarker Study | Biotech Hunter | Biotech Hunter